United Therapeutics Q2 2024 revenue up 20% to $714.9M, EPS $5.85

UNITED THERAPEUTICS Corp

2024-Q2 EPS reported $12.03 revenue$1,392,600,000

Total revenues $714.9M (+20% YoY); net income $278.1M ($5.85 diluted EPS) vs $259.2M ($5.24) in Q2 2023.
Tyvaso products revenue $398.2M (+25% YoY), led by Tyvaso DPI growth from PH-ILD launch.
Remodulin $147.3M (+16%), Orenitram $107.1M (+13%), Unituxin $51.7M (+17%).
R&D expense rose 57% to $139.6M, driven by upfront licensing payments and organ manufacturing.
Completed $300M tranche of $1B ASR; final $700M settlement expected in Q3 2024.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.